<DOC>
	<DOCNO>NCT02047565</DOCNO>
	<brief_summary>This Phase 1 study consist 2 part . Part 1 open-label , randomize , 2 treatment , 2-way crossover study . Part 2 double-blind ( Sponsor unblinded ) , randomize , placebo control , sequential descend prothrombin complex concentrate dose , 2 sequence , 2 period crossover study . In part study , assessor BD BV remain blinded . In Part 2 study , subject clinic staff involve study conduct blind ( exception pharmacist nurse prepares blind individual treatment open-label supply ) . The study programmer statistician also blind treatment assignment . The Sponsor remain unblinded part study .</brief_summary>
	<brief_title>A Two-part Study Edoxaban-treated Healthy Subjects Establish Punch Biopsy Bleeding Model Evaluate Effect 4-factor Prothrombin Complex Concentrate Anticoagulation</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Healthy subject 18 45 year age , body mass index 18 30 kg/m2 , weigh ≤ 110 kg . Women childbearing potential without proper contraceptive measure woman pregnant breastfeeding . Women childbearing potential participate study must agree use proper contraceptive measure screen 13 week last dose study drug . Subjects history unexplained syncope . Subjects prior clearance vasovagal event may include . Subjects use drug substance know strong inhibitor strong inducer cytochrome P450 ( CYP ) 3A4/5 enzyme Pglycoprotein within 28 day prior first dose . Subjects use nonprescription drug ( include herbal supplemental ) , except acetaminophen ( 3 g/day ) within 14 day prior checkin . Subjects history major bleeding , major trauma , major surgical procedure type within 6 month dose . Subjects history peptic ulcer , gastrointestinal bleeding ( include hematemesis , melena , rectal bleeding ) , bleed hemorrhoid . Subjects history minor bleeding episode epistaxis , rectal bleeding ( spots blood toilet paper ) , gingival bleeding within 3 month first dose . Subjects family history , suspect document , coagulopathy . Subjects participate previous edoxaban study within 6 month prior first dose . Subjects use anticoagulant ( eg , warfarin , low molecular weight heparin ) , antiplatelet agent ( eg , clopidogrel ) , nonsteroidal antiinflammatory drug , and/or acetylsalicylic acid 30 day prior punch biopsy expect use study . Subjects hemoglobin level 12 g/dL ( men ) 11 g/dL ( woman ) screen . Subjects creatinine clearance ≤ 80 mL/min ( base CockcroftGault equation ) . Subjects consider inappropriate punch biopsy procedure base inability visualize surface blood vessel , history likelihood form keloid scar . Subjects know heparininduced thrombocytopenia . Subjects platelet count , PT , INR outside normal range baseline . Subjects history current evidence clinically significant cardiac , hepatic , renal , pulmonary , endocrine , neurologic , infectious , gastrointestinal , hematologic , oncologic disease determine screen history , physical examination , laboratory test result , 12lead electrocardiogram ( ECG ) . In addition , Part 2 : Subjects deficient Factor V Leiden mutation . Subjects deficient protein S , protein C , antithrombin , factor II , prothrombin 20210A mutation . Subjects know anaphylactic severe systemic reaction Beriplex P/N component Beriplex P/N include heparin ; FII , FVII , FIX , FX ; proteins C S ; antithrombin III ; human albumin . Subjects current history disseminate intravascular coagulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>punch biopsy</keyword>
</DOC>